Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Lung cancer screening: Should we be excluding people with previous malignancy?
Cherie P Erkmen, Larry R Kaiser, Department of Thoracic Medicine and Surgery, Temple University Health System, Philadelphia, PA 19140, United States
Ashley L Ehret, Department of Surgery, Temple University Health System, Philadelphia, PA 19140, United States
Author contributions: Erkmen CP is the primary researcher and author of the manuscript; Ehret AL and Kaiser LR contributed to literature review, evaluation, analysis, writing, revising and formatting the manuscript.
Conflict-of-interest statement: Erkmen CP, Kaiser LR and Ehret AL have no conflicts of interest to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Cherie P Erkmen, MD, Associate Professor of Surgery, Director of The Temple-Fox Chase Lung Cancer Screening Program, Department of Thoracic Medicine and Surgery, Temple University Health System, 3401 North Broad Street, Philadelphia, PA 19140, United States. cherie.p.erkmen@tuhs.temple.edu
Telephone: +1-215-7079115 Fax: +1-215-70791131
Received: September 28, 2015
Peer-review started: September 28, 2015
First decision: November 30, 2015
Revised: January 19, 2016
Accepted: March 14, 2016
Article in press: March 16, 2016
Published online: March 28, 2016
Peer-review started: September 28, 2015
First decision: November 30, 2015
Revised: January 19, 2016
Accepted: March 14, 2016
Article in press: March 16, 2016
Published online: March 28, 2016
Core Tip
Core tip: Most lung cancer screening trials, including the National Lung Screening Trial, exclude those with a history of a previous malignancy as it may introduce confounding factors that influence survival. However, people with previous malignancy may benefit from the discovery of treatable lung cancer as well as treatable metastasis. In this review, we summarize the consideration that studies and national guidelines give in regards to lung cancer screening in patients with previous malignancy. Furthermore, we address the implications of lung cancer screening in the setting of specific malignancies, namely lung, head and neck, esophageal, gastric, breast, colorectal cancer and lymphoma.